Clinical Trials Logo
  1. Home
  2. Generalized Pustular Psoriasis
  3. NCT05366855

Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis — GEMINI2  

Generalized Pustular Psoriasis Clinical Trial

Official title:
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis

Clinical Trial Summary

This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).

Clinical Trial Description

This study will also evaluate the pharmacokinetic (PK) profile of imsidolimab and explore the immunogenicity of imsidolimab in subjects with GPP ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05366855
Study type Interventional
Source AnaptysBio, Inc.
Contact
Status Active, not recruiting
Phase Phase 3
Start date April 21, 2022
Completion date December 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06100991 - CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
Recruiting NCT06013969 - A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares Phase 4
Completed NCT05512598 - HB0034 in Patients With Generalized Pustular Psoriasis (GPP) Phase 1
Active, not recruiting NCT03886246 - Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study Phase 2
Recruiting NCT05670821 - PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
Recruiting NCT06323356 - A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Phase 3
Completed NCT05239039 - An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options Phase 3
Completed NCT04399837 - A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis Phase 2
Not yet recruiting NCT06433531 - A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) Phase 1
Completed NCT03942042 - A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Phase 4
Completed NCT06391996 - Biologic Therapy for Generalized Pustular Psoriasis
Completed NCT03782792 - Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis Phase 2
Completed NCT03619902 - A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis Phase 2
Active, not recruiting NCT04566471 - Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
Recruiting NCT06295692 - A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Phase 3
Completed NCT05200247 - An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options Phase 3
Completed NCT05352893 - Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP Phase 3